Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04338399
Registration number
NCT04338399
Ethics application status
Date submitted
18/03/2020
Date registered
8/04/2020
Date last updated
2/11/2023
Titles & IDs
Public title
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Query!
Scientific title
The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Query!
Secondary ID [1]
0
0
AN2025H0301
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
BURAN
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Head and Neck Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Head and neck
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Buparlisib & Paclitaxel
Experimental: Buparlisib & Weekly Paclitaxel - Drug: Patients will receive 100 mg (2 x 50 mg) buparlisib hard gel capsule administered orally, once daily starting on Day 1 of Treatment Cycle 1, Drug: Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle.
Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason.
Active Comparator: Weekly Paclitaxel - Patients will receive weekly paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle. Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason.
Treatment: Drugs: Buparlisib & Paclitaxel
Investigation drug plus paclitaxel
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
To assess the OS of buparlisib in combination with paclitaxel compared to paclitaxel alone in patients with recurrent or metastatic HNSCC
Query!
Timepoint [1]
0
0
Overall survival will be measured from time of randomization until death from any cause. The analysis will occur when all patients have been randomized and followed for 12 months.
Query!
Secondary outcome [1]
0
0
Progression free survival
Query!
Assessment method [1]
0
0
Defined as the time from randomization date until tumor progression or death from any cause.
Query!
Timepoint [1]
0
0
PFS will be assessed up to 24 months after all patients are randomized
Query!
Secondary outcome [2]
0
0
Overall Response Rate
Query!
Assessment method [2]
0
0
Defined at the proportion of patients with a complete or partial response
Query!
Timepoint [2]
0
0
ORR will be assessed for all patients 6 months after randomization is complete.
Query!
Secondary outcome [3]
0
0
Health Related Quality of Life (QoL): Time to Definitive deterioration of Quality of Life as assessed by EORTC C30 questionnaire
Query!
Assessment method [3]
0
0
A summary of EORTC-QLQ-C30 scores by time window. Time to deterioration is the number of days between the date of randomization and the date of the assessment when definitive deterioration is seen. Definitive deterioration is defined as a decrease in the sub scale score by at least 10% compared with baseline.
Query!
Timepoint [3]
0
0
Assessments will be made from randomization until treatment discontinuation
Query!
Secondary outcome [4]
0
0
Safety and Tolerability of Buparlisib in combination with Paclitaxel compared with Paclitaxel alone as Measured by Number of Participants Experiencing Adverse Events (AEs).
Query!
Assessment method [4]
0
0
Treatment Emergent Adverse Events AEs will be assessed according to the NCI-CTCAE version 5.0 for severity and will be recorded and classified on the basis of MedDRA terminology.
Anxiety score change from baseline taken at time of screening (General Anxiety Disorder 7 item scale) until end of treatment.
Depression score change from baseline taken at time of screening (Patient Health Questionnaire 9) until end of treatment.
Query!
Timepoint [4]
0
0
From screening until 4 weeks following treatment discontinuation
Query!
Secondary outcome [5]
0
0
Pharmacokinetics of Buparlisib: plasma concentration-time profile of Buparlisib during 15 days of treatment
Query!
Assessment method [5]
0
0
For Sparse PK sampling, blood samples will be collected on Treatment Cycle 1, Days 1, 8, and 15 at pre-dose, 1 (± 0.25), 2 ± (0.25) and 6 ± (0.5) hours post-dose. PK sampling will be collected only for those patients randomized to the buparlisib in combination with paclitaxel arm and pharmacokinetic profile of Buparlisib combined with paclitaxel in the study population will be compared with a simulated population PK model.
Query!
Timepoint [5]
0
0
Day 0 to Day 15 sparse sampling
Query!
Eligibility
Key inclusion criteria
1. Aged =18 years old.
2. Able to provide informed consent obtained before any trial related activities and
according to local guidelines.
3. Patient has histologically and/or cytologically-confirmed HNSCC.
4. Patient has archival or new tumor tissue for the analysis of biomarkers and
confirmation of HPV status (if unknown). One tumor block (preferred) or a recommended
minimum of 5 unstained slides for patients with known HPV status (for tumor DNA
characterization) or a recommended minimum of 10 slides for patients whose HPV status
is unknown (5 slides for HPV testing plus 5 slides needed for biomarker testing).
Enrollment in the study is contingent on confirmation of the availability of an
adequate amount of tumor tissue, except in rare special circumstances, which must be
reviewed and approved by the sponsor.
5. Patient has either progressive or recurrent disease after treatment with PDL1/PD1
based therapy for recurrent or metastatic disease:
1. PDLl/PD1 therapy alone for metastatic (monotherapy) disease
2. PDL1/PD1 in combination with chemotherapy for metastatic and recurrent disease
3. PDL1/PD1 used for metastatic disease, after or prior to receiving a platinum
agent for locally advanced or metastatic disease.
6. 6. Patient has received no more than two prior lines of systemic treatment for HNSCC
(single agent chemotherapy used as a radiosensitizer is not counted as a prior line of
therapy).
7. Patient has measurable disease as determined per RECIST version 1.1. If the only site
of measurable disease is a previously irradiated lesion, documented progression of
disease and a four-week period since radiotherapy completion is required.
8. Patient has adequate bone marrow function and organ function as shown by the
following:
1. Absolute neutrophil count (ANC) =1.5 x 109/L.
2. Hemoglobin =9 g/dL (which may be reached by transfusion).
3. Platelets =100 x 109/L (which may be reached by transfusion).
4. International normalized ratio (INR) =1.5.
5. Calcium (corrected for serum albumin) within normal limits (WNL) or = grade 1
severity according to NCI-CTCAE version 5.0 if judged clinically not significant
by the Investigator.
Patients concomitantly taking bisphosphonates or denosumab for calcium correction
are eligible.
6. Normal potassium and magnesium levels.
7. Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) = 1.5 x upper
limit of normal (ULN) or < 3.0 x ULN if liver metastases are present.
8. Total serum bilirubin = ULN or = 1.5 x ULN if liver metastases are present; or
total bilirubin = 3.0 x ULN with direct bilirubin below or within normal range in
patients with well documented Gilbert's Syndrome. Gilbert's syndrome is defined
as presence of episodes of unconjugated hyperbilirubinemia with normal results
from cells blood count (including normal reticulocyte count and blood smear),
normal liver function test results, and absence of other contributing disease
processes at the time of diagnosis.
9. Serum creatinine = 1.5 x ULN or calculated and directly measured creatinine
clearance (CrCL) > 30 mL/min.
10. Haemoglobin A1c (glycosylated hemoglobin; HbA1c) =8%.
9. Patient has Eastern Cooperative Oncology Group (ECOG) performance status =1.
10. Patient is able to swallow and retain oral medication. Patients able to swallow oral
medication but mostly self-nourished through gastric or jejunal feeding tube are
eligible.
11. Patients must apply highly effective contraception during and throughout the study, as
well after the final dose of study treatment
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients meeting any of the following criteria will not be eligible for participation in
the study:
1. Patient has received previous treatment with any protein kinase B (PKB/AKT), mammalian
target of rapamycin (mTOR) inhibitors, or phosphatidylinositol 3 kinase (PI3K) pathway
inhibitors.
2. Patient received treatment with a taxane as part of prior treatment for metastatic
disease.
3. Patient has symptomatic central nervous system (CNS) metastases. Patients with
asymptomatic CNS metastases may participate in this study. Patient must have completed
any prior local treatment for CNS metastases = 28 days prior to the start of study
treatment (including radiotherapy) and must be on a stable low dose of corticosteroid
therapy. Radiosurgery must have been completed at least 14 days prior to start of
study treatment.
4. Patient has received wide field radiotherapy = 4 weeks or limited field radiation for
palliation = 2 weeks prior to starting study treatment or who have adverse events
which have not recovered to grade 1 or better from previous chemotherapy treatment
(except alopecia, autoimmune endocrine events must be stable and controlled).
5. Patient has grade = 2 neuropathy, colitis, pneumonitis, , and uncontrolled
endocrinopathies (e.g., hypothyroidism, diabetes with hemoglobin A1c > 8%) from
previous treatment
6. Patient has had major surgery within 14 days prior to starting study treatment or has
not recovered from major side effects.
7. Patient is currently receiving increasing or chronic treatment (>5 days) with
corticosteroids or another immunosuppressive agent. The following uses of
corticosteroids are permitted: single doses; standard premedication for paclitaxel,
topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways
diseases), eye drops, or local injections (e.g., intra-articular), or < 10 mg
prednisolone or equivalent.
8. Patient is being treated at start of study treatment with any of the following drugs:
1. Drugs known to be strong or moderate inhibitors or inducers of isoenzyme
cytochrome P450 3A4 (CYP3A4) including herbal medications (see Table 16).
2. Drugs with a known risk of inducing Torsades de Pointes. Note: The patient must
have discontinued strong inducers for at least one week and must have
discontinued strong inhibitors before the treatment is initiated. Switching to a
different medication prior to starting study treatment is allowed.
9. Patient is currently receiving warfarin or other coumarin-derived anti-coagulant, for
treatment, prophylaxis, or otherwise. Therapy with heparin, low molecular weight
heparin (LMWH), fondaparinux or new oral anticoagulants (NOACs) is allowed.
10. Patient has a known hypersensitivity and/or contraindication to paclitaxel, standard
premedication for paclitaxel, or other products containing Cremophor®.
11. Patient has other concurrent severe and/or uncontrolled medical conditions that would,
in the Investigator's judgment, contraindicate patient participation in the clinical
study (e.g., active or uncontrolled severe infection, chronic active hepatitis,
immunocompromised, acute or chronic pancreatitis, uncontrolled high blood pressure,
interstitial lung disease, etc).
12. Patient has a known history of human immunodeficiency virus (HIV) infection (testing
not mandatory).
13. Patient has any of the following cardiac abnormalities:
1. Symptomatic congestive heart failure within 12 months of the screening period.
2. History of documented congestive heart failure (New York Heart Association
functional classification III-IV) or documented cardiomyopathy and left
ventricular ejection fraction (LVEF) <50% as determined by multiple gated
acquisition (MUGA) scan or echocardiogram (ECHO).
3. Myocardial infarction =six months prior to enrollment.
4. Unstable angina pectoris.
5. Serious uncontrolled cardiac arrhythmia.
6. Symptomatic pericarditis.
7. QT interval corrected according to the formula of Fridericia (QTcF) > 450 msec
for males and > 470 msec for females, on the screening electrocardiogram (ECG).
8. Currently receiving treatment with medication that has a known risk to prolong
the QT interval or inducing Torsades de Pointes, and the treatment cannot be
discontinued or switched to a different medication prior to starting study
treatment.
14. Patient has impairment of gastrointestinal (GI) function or GI disease that may
significantly alter the absorption of study treatment (e.g., ulcerative diseases,
uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel
resection).
15. Patient has a medically documented history of or active major depressive episode,
bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of
suicidal attempt or ideation, or homicidal ideation (e.g., risk of doing harm to self
or others), or active severe personality disorders (defined according to the
Diagnostic and Statistical Manual of Mental Disorders Fifth Edition [DSM-V]) are not
eligible. Note: For patients with psychotropic treatments ongoing at baseline, the
dose and the schedule should not be modified within the previous six weeks prior to
start of study treatment.
16. Patient has other prior or concurrent malignancy except for the following: adequately
treated basal cell or squamous cell skin cancer, or other adequately treated in situ
cancer, early gastric or GI cancer resected completely by endoscopy procedures or any
other cancer from which the patient has been disease free for = 3years.
17. Patient has a history of non-compliance to any medical regimen or inability to grant
consent.
18. Patient is concurrently using or has used another approved or investigational cancer
agent within 4 weeks of randomization.
19. Patient is pregnant or nursing (lactating). Patients with elevated human chorionic
gonadotrophin (hCG) at baseline that is judged to be related to the tumor are eligible
if hCG levels do not show the expected doubling when repeated five to seven days
later, or pregnancy has been ruled out by vaginal ultrasound.
20. Patient has received a live vaccine within 30 days of planned start of study therapy.
Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines
and are allowed; however intranasal influenza vaccines (eg, Flu-Mist®) are live
attenuated vaccines, and are not allowed. Non-live COVID vaccinations or boosters
should not occur within 30 days of study start.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/12/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/06/2026
Query!
Actual
Query!
Sample size
Target
483
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Princess Alexandra Hospital - Brisbane
Query!
Recruitment postcode(s) [1]
0
0
4102 - Brisbane
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kentucky
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Missouri
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
South Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Tennessee
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Buenos Aires
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Ciudad Autonoma de Buenos Aire
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Córdoba
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
La Rioja
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Tucuman
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Ghent
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Jette
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Liege
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Ottignies
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Montreal
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Winnipeg
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Beijing
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Bengbu
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Changsha
Query!
Country [30]
0
0
China
Query!
State/province [30]
0
0
Chengdu
Query!
Country [31]
0
0
China
Query!
State/province [31]
0
0
Chongqing
Query!
Country [32]
0
0
China
Query!
State/province [32]
0
0
Guangzhou
Query!
Country [33]
0
0
China
Query!
State/province [33]
0
0
Hangzhou
Query!
Country [34]
0
0
China
Query!
State/province [34]
0
0
Hefei
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Jinan
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
Kunming
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Naning
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Shanghai
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Tianjin
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Zhengzhou
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Zhuhai
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Bordeaux
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Caen
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Lyon
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Marseille
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Montpellier
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Nantes
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Neuilly Sur Seine
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Paris
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Saint-Grégoire
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
VandÅ“uvre-lès-Nancy
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Aachen
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Bonn
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Essen
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Georgsmarienhütte
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Giessen
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Greifswald
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Hamburg
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Hannover
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Leipzig
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Mainz
Query!
Country [62]
0
0
Hong Kong
Query!
State/province [62]
0
0
Hong Kong
Query!
Country [63]
0
0
Hungary
Query!
State/province [63]
0
0
Budapest
Query!
Country [64]
0
0
Hungary
Query!
State/province [64]
0
0
Pécs
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Szekszárd
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Bologna
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Brescia
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Candiolo
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Cesena
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Cuneo
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Firenze
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Milano
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Milan
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Napoli
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Novara
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Palermo
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Parma
Query!
Country [78]
0
0
Italy
Query!
State/province [78]
0
0
Pavia
Query!
Country [79]
0
0
Italy
Query!
State/province [79]
0
0
Rozzano
Query!
Country [80]
0
0
Italy
Query!
State/province [80]
0
0
Salerno
Query!
Country [81]
0
0
Italy
Query!
State/province [81]
0
0
Siena
Query!
Country [82]
0
0
Italy
Query!
State/province [82]
0
0
Sondrio
Query!
Country [83]
0
0
Italy
Query!
State/province [83]
0
0
Tricase
Query!
Country [84]
0
0
Italy
Query!
State/province [84]
0
0
Udine
Query!
Country [85]
0
0
Italy
Query!
State/province [85]
0
0
Verona
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Akashi-shi
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Chuo Ku
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Fukuoka shi
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Hidaka
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Kita-gun
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Kobe
Query!
Country [92]
0
0
Japan
Query!
State/province [92]
0
0
Koto-Ku
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Matsuyama
Query!
Country [94]
0
0
Japan
Query!
State/province [94]
0
0
Nagoya
Query!
Country [95]
0
0
Japan
Query!
State/province [95]
0
0
Osaka Sayama-shi
Query!
Country [96]
0
0
Japan
Query!
State/province [96]
0
0
Sapporo
Query!
Country [97]
0
0
Japan
Query!
State/province [97]
0
0
Sendai
Query!
Country [98]
0
0
Japan
Query!
State/province [98]
0
0
Shinagawa-Ku
Query!
Country [99]
0
0
Japan
Query!
State/province [99]
0
0
Shizuoka
Query!
Country [100]
0
0
Korea, Republic of
Query!
State/province [100]
0
0
Busan
Query!
Country [101]
0
0
Korea, Republic of
Query!
State/province [101]
0
0
Incheon
Query!
Country [102]
0
0
Korea, Republic of
Query!
State/province [102]
0
0
Seongnam-si
Query!
Country [103]
0
0
Korea, Republic of
Query!
State/province [103]
0
0
Seoul
Query!
Country [104]
0
0
Korea, Republic of
Query!
State/province [104]
0
0
Suwon-si
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Gliwice
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Warszawa
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
A Coruña
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Badalona
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Barcelona
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Burgos
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Córdoba
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Hospitalet de Llobregat
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Jaén
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Leganés
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Lugo
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Madrid
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Majadahonda
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Málaga
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Pamplona
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Santander
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Santiago De Compostela
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Sevilla
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Valencia
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Zaragoza
Query!
Country [125]
0
0
Taiwan
Query!
State/province [125]
0
0
Changhua
Query!
Country [126]
0
0
Taiwan
Query!
State/province [126]
0
0
Kaohsiung
Query!
Country [127]
0
0
Taiwan
Query!
State/province [127]
0
0
Taichung
Query!
Country [128]
0
0
Taiwan
Query!
State/province [128]
0
0
Tainan
Query!
Country [129]
0
0
Taiwan
Query!
State/province [129]
0
0
Taipei
Query!
Country [130]
0
0
Taiwan
Query!
State/province [130]
0
0
Taoyuan
Query!
Country [131]
0
0
United Kingdom
Query!
State/province [131]
0
0
Edinburgh
Query!
Country [132]
0
0
United Kingdom
Query!
State/province [132]
0
0
Glasgow
Query!
Country [133]
0
0
United Kingdom
Query!
State/province [133]
0
0
London
Query!
Country [134]
0
0
United Kingdom
Query!
State/province [134]
0
0
Sutton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Adlai Nortye Biopharma Co., Ltd.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The BURAN study is a randomized, open-label phase III study to assess the treatment effect of
once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel
alone in patients with refractory, recurrent, or metastatic head and neck squamous cell
carcinoma (HNSCC) that have progressed after prior anti PD 1/anti PD L1 monotherapy; prior
anti PD 1/anti PD L1 therapy in combination with platinum-based therapy; or after sequential
treatment of anti PD 1/anti PD L1 therapy, either prior to or post, platinum-based therapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04338399
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Senior Director, Global Operations
Query!
Address
0
0
Adlai Nortye USA Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04338399
Download to PDF